What is the current stock price of Chemomab Therapeutics Ltd. (CMMB)?

As of the latest market data, Chemomab Therapeutics Ltd. (CMMB) is trading at $1.99. The stock has seen a loss of -1.97% today.

Does Chemomab Therapeutics Ltd. (CMMB) pay a dividend?

Based on current data, Chemomab Therapeutics Ltd. does not have a confirmed active dividend policy.

What is the market cap of Chemomab Therapeutics Ltd.?

The current market capitalization of Chemomab Therapeutics Ltd. (CMMB) is approximately unavailable.

CMMB

Chemomab Therapeutics Ltd.·Healthcare

1.99

1.970%(−0.04)

Market Open

Last Updated: — ET

52W L: $1.3552W H: $5.72

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2019-02-12

Beta

0.51

Websitewww.chemomab.com↗